Abstract
Caenorhabditis elegans is an appealing tool for experimental evolution and for working with antiparasitic drugs, from understanding the molecular mechanisms of drug action and resistance to uncover new drug targets. We present a new methodology for studying the impact of antiparasitic drugs in C. elegans. Viscous medium was initially designed for C. elegans maintenance during long-term evolution experiments. Viscous medium provides a less structured environment than the standard nematode growth media agar, yet the bacteria food source remains suspended. Further, the Viscous medium offers the worm population enough support to move freely, mate, and reproduce at a rate comparable to standard agar cultures. Here, the Viscous medium was adapted for use in antiparasitic research. We observed a similar sensitivity of C. elegans to anthelmintic drugs as in standard liquid media and statistical difference to the standard agar media through a larval development assay. Using Viscous medium in C. elegans studies will considerably improve antiparasitic resistance research, and this medium could be used in studies aimed at understanding long-term multigenerational drug activity.
Keywords: Caenorhabditis elegans, Anthelmintics, Viscous medium, Larval development
Subject terms: Caenorhabditis elegans, Drug delivery, Animal disease models
Introduction
Caenorhabditis elegans occurs in temperate regions of the world, where it commonly inhabits decaying plant matter and feeds on diverse microorganisms1. These worms are maintained in the laboratory on nematode growth agar media (NGM) agar and have a typical growth cycle of 3.5 days at 20 °C2. Sydney Brenner introduced them into the laboratory to study animal development and their nervous system. Since then, they have become one of the main model systems in biomedical research across diverse fields, including e.g. research on aging, host–pathogen interactions, cell division, cytoskeleton, and drug discovery3–6.
Caenorhabditis elegans has been used as a model for parasitic worms to understand the mechanism of many anthelmintics and is involved in drug discovery7–11. These worms are a valuable model in anthelmintic research as parasitic worms are impossible to cultivate in the laboratory, with the exception of Parastrongyloides trichosuri12 and lack the same genetic tools as C. elegans.
Anthelmintics studied in C. elegans include macrocyclic lactones, benzimidazoles, imidazothiazoles, spiroindoles, cyclooctadepsipeptides, and Crystal (Cry) proteins from Bacillus thuringiensis11,13–18. Macrocyclic lactones interact with ligand-gated ion channels, in particular glutamate-gated chloride channels (GluCls) and in nematodes to a lesser extent to GABA-gated chloride channels19. Ivermectin (IVM), a member of the macrocyclic lactones, binds irreversibly to GluCls, which allows an influx of chloride ions, ultimately causing paralysis of the neuronal or muscular membrane20. Often, in worms, the pharynx muscles are targeted as well, thus inhibiting the feeding of the worm, and leading to starvation18. Therefore, IVM affects both the motility and feeding of the nematode. Moxidectin (MOX) also targets GluCls but has different pharmacokinetics than IVM19. The different pharmacokinetics are often considered to be the reason for the higher potency of MOX compared to IVM against resistant isolates of parasitic nematodes in sheep, cattle, horses, and goats21. In motility assays using C. elegans often slightly higher concentrations of MOX than of IVM are required to achieve half maximal effect change22, which can be reversed if worms do not feed, suggesting that both drugs enter the worms via different routes23. Benzimidazoles work as anthelmintics by binding to the β-tubulin subunit and preventing microtubule polymerization, inhibiting the microtubule dynamics needed for cells to survive and divide24,25. Without the microtubule dynamics within the cell, the worms often become flaccid and paralyzed25,26. Lastly, imidazothiazoles are broad-spectrum drugs that act on nicotinic acetylcholine receptors (nAChRs). Of this class, levamisole is the only licensed and most commonly studied drug that targets the body wall muscles and causes spastic paralysis of worms27.
Usually, in in vitro assays, C. elegans are exposed to the drugs by placing them on nematode growth medium (NGM) agar plates containing the desired concentration of the drug. Nematode growth medium agar was first introduced as a viable media source by Sydney Brenner in 19742. Although this medium is helpful for the easy maintenance of a population and is commonly used for various genetic manipulations such as RNAi and behavioral avoidance experiments, it is limited in effectively characterizing the effects of drugs on a worm population. This is due to the highly dense matrix of the NGM agar, which is maintained to prevent worm burrowing. Organic compounds used as drugs are typically dissolved in DMSO. They often have limited effect on worms on NGM agar due to the little surface area exposed to the drugs at any given time28,29. Moreover, the drug has to be added to molten agar (> 55 °C temperature), rapidly mixed and poured into petri dishes. Further NGM agar is a highly complex mixture with undefined compounds of agar and bactopeptone. We speculate that these compounds could decrease the solubility of a drug and lead to it precipitating in NGM agar. By this study design, it is difficult to guarantee a homogenous distribution of the drug in the agar and exclude any temperature dependent drug degradation. Therefore, testing drugs in a liquid-based medium is more desirable to identify their effects on worm populations. One liquid-based medium is liquid NGM which is NGM agar but without agar, it is commonly used for chemical and RNAi screens8,30. Another liquid medium, the so-called S medium, is the commonly used liquid medium in C. elegans research31. It is composed of phosphate buffer with essential additives such as cholesterol, trace metals, magnesium sulfate, and calcium chloride. Unfortunately, S medium does not allow maintenance of worm populations for much more than one generation. This is due to considerable effects on the worm phenotype/morphology such as dauer formation despite the presence of food31. Also, worms grown in liquid cultures are often thinner, longer, and often retain their eggs in comparison to worms grown on agar31,32. Therefore, any study trying to understand the effects of drugs in an experiment spanning multiple generations such as evolution has limited media sources to use.
Papkou et al.33 developed a new Viscous medium (V medium), consisting of S medium supplemented with a nontoxic agent increasing the viscosity of the medium, hydroxypropylmethylcellulose (HPMC), for long-term evolution experiments and high-throughput assays. An initial characterization of V medium with 0.5% methylcellulose revealed that it supports a high efficiency in mating between hermaphrodites and males (indicated by a male ratio between 0.3 and 0.4) and offspring production (e.g., 30–50 offspring per worm after a six day incubation at 16 °C)8,28, 33. The previous study used the medium to characterize the coevolutionary dynamics between C. elegans as host and bacterial pathogens, demonstrating a more complex model of the Red Queen, consisting of distinct selective processes acting on the two antagonists during rapid and reciprocal coadaptation33.
Based on the previous work by Papkou et al. 2019, the objectives of the current study were to develop the V medium further as a basis for dissecting the interaction of the C. elegans model with different anthelmintics. In particular, the V medium was tested in larval development assays in comparison to the S medium to determine inferred EC50 values and the suitability of V medium for evaluating the effects of anthelmintics.
Methods
Worm strains and maintenance and chemicals
Caenorhabditis elegans P-glycoprotein 9 knock-out strain tm830 was obtained from the NBRP. Worms were maintained on nematode growth agar media (NGM) agar supplemented with E. coli OP50 as a food source at 16 °C using standard manipulation methods (Hope, 1999). Ivermectin (#I8898), moxidectin (#33,746), levamisole (#31,742), and albendazole (A4673) were obtained from Sigma-Aldrich and stored at − 20 °C.
Viscous medium
V medium has a base of S basal buffer (10 mM Potassium phosphate buffer pH 6.0, 100 mM NaCl). The 450 ml of S basal was heated to 60–70 °C and 4.6 g of (Hydroxypropyl)methylcellulose (H7509, Sigma) was added slowly under constant stirring. The solution was then autoclaved and allowed to cool down. After autoclaving the medium was stirred for 30 min under gentle heat (30–40 °C) until the medium was homogenous. Before use, 10 ml of 1 M potassium citrate pH 6.0, 1.5 ml of 1 M Mg2SO4, 1.5 ml of 1 M CaCl2, and 0.5 ml of 5 mg/ml cholesterol (in 100% ethanol) were added. The media was stored at 4 °C.
Escherichia coli OP50 preparation
Escherichia coli OP50 (C. elegans Genetic Stock Center, https://cgc.umn.edu/) was used as a food source for C. elegans. Cultures were initiated from a -80 frozen stock and struck out on LB agar (Carl Roth, Germany). Overnight cultures were grown from picking of a single OP50 colony in 500 ml of LB-broth (Carl Roth, Germany) at 37 °C, 200 rpm for 16–20 h. The cells were then pelleted and washed with S basal in 50 ml tubes (4000 rpm, 30 min). Escherichia coli pellets (~ 2 g) were resuspended in 20 ml of S basal. The optical density of the E. coli was measured at 600 nm using a 1:100 dilution of the final resuspended E. coli pellet. The concentrated E. coli were stored at 4 °C for 2 weeks until further use.
Adaptation of C. elegans worms to viscous medium
Caenorhabditis elegans tm830 worms were grown in a 6-well plate in 3.2 ml of V medium supplemented with 10 mM potassium citrate (pH 6.0), 3 mM Mg2SO4, 3 mM CaCl2, 5 µg/ml cholesterol with OP50 as a food source (final optical density OD600 = 1.5). The worms were incubated at 20 °C for 4 days. The wells were washed with 4 ml of S basal to ease the pipetting of the V medium. The worm media mixture was transferred to a 50 ml centrifugation tube and spun at 5134 × g (Eppendorf 5430R) for 5 min at 20 °C. The supernatant was removed, and the worms were placed on top of two layered 150 mm filter papers (Carl Roth Typ600P, #CA20.1) and washed with 100 ml of S basal to remove all remaining V medium (Fig. 1). The worm density was estimated by counting 10 5 µl drops of worms. 3000 worms were placed in each well of a 6-well plate and incubated at 20 °C for 4 days with constant shaking at 150 rpm.
Synchronization of worms from viscous medium
F2 generation gravid hermaphrodites were washed by adding an equal volume of S basal to each well. The worms were put in a 50 ml centrifugation tube and centrifuged at 5134 × g (Eppendorf 5430R) for 5 min. The supernatant was removed, and the worms were washed as described above and resuspended in 20 ml S basal. A 2 × bleaching solution (1.2% household bleach and 700 mM NaOH) was prepared. The bleaching solution was added at an equal volume to the worm suspension, and it was vortexed on high speed for 6 min, checking for lysis periodically. The bleach/worm suspension was centrifuged for 1.5 min at 5134 × g at 20 °C. The worms were washed three times with 20 ml of S basal and resuspended in 15 ml S basal for incubation overnight at 20 °C with constant shaking at 150 rpm.
Growth rates in viscous medium
Synchronized C. elegans tm830 worms (approximately 1000) at the first larval (L1) stage were added to each well of a 6-well plate containing 3.2 ml of V medium and E. coli OP50 as a food source (final OD600 = 1.0). Worms were incubated at 20 °C with constant shaking at 150 rpm. Every 24 h, the worms were visualized with a stereomicroscope (Leica MZ 16F) by the removal of 150 µl of media (~ 100 worms) and placed on NGM agar with 10 mM levamisole to paralyze them to image the developing anatomical structures. Four wells were counted at each time point, which was done with 3 biological replicates (n = 12 replicates in total). For each well, the number of all larval stages was counted, and a fraction of the larval stages was determined and averaged. The averages for each biological replicate were graphed with GraphPad Prism 5.0, and the standard deviations and means were determined.
Worm length and width
Synchronized L1 tm830 worms obtained by bleaching were counted, and approximately 50 worms in quadruplicate were added to 1 ml of S or V medium in a 24 well plate supplemented with E. coli OP50 (final OD600 = 1). Approximately 60 worms were seeded onto 2 day old NGM agar spotted with E. coli OP50. All worms were placed in incubators at 20 °C, with the S and V medium under constant shaking at 150 rpm. After 96 h approximately 30 worms per replicate for each media condition were imaged. Images were collected by ISOCELL HP2 camera and processed using Wormsizer (v 1.2.5). Worm length and mean width were plotted in GraphPad Prism (v 5.0) with mean and standard error shown. P values were obtained by one-way ANOVA with post test of Tukey’s multiple comparison test. Not significant (ns) indicates a P value above 0.05, * indicates a P value below 0.05, and *** indicates a P value lower than 0.0001.
Larval development assay
For assays with S basal, synchronized L1 tm830 worms obtained by bleaching were counted, and approximately 100 worms were added in 24 µl S basal to every well of a 48-well microtiter plate already containing 200 µl S medium, 25 µl E. coli OP50 (OD600 = 2), and 1 µl anthelmintic was added. For all anthelmintics, serial dilutions were prepared in 100% DMSO or S basal (levamisole). For ivermectin, the final concentration range was 0.07–8 nM with a 1.4 fold dilution between concentrations, 0.02–6 nM with a 1.5 fold dilution for moxidectin, 0.9–100 µM with a 1.4 fold dilution for levamisole, and 2–600 µM with a 1.5 fold dilution for albendazole. Drug concentrations were done in triplicate, and four biological replicates were done on different days for each drug/medium combination. Worms were incubated at 20 °C with constant shaking at 150 rpm. After a 48–55 h incubation, the development was stopped by adding Lugol's iodine. Worms that developed into either the L4 or adult stage were counted as fully developed, while L1, L2, and L3 were considered not developed. The EC50 values were determined by performing the variable slope log10(inhibitor concentration) vs. percent development response curve as logistic regression (Variable slope (four parameters)) analysis using GraphPad Prism 5.0. EC50 values were compared using the extra sum of squares F-test within GraphPad Prism. P values < 0.05 were considered to be statistically significant.
Experiments with V medium were performed as described for S basal, but the C. elegans tm830 worms synchronized for the larval development assay had been grown in V medium in a 6-well plate with 3000 worms per well for 2 generations prior to the experiment. Each generation was transferred as described above. Every well of a 48-well microtiter plate had 200 µl V medium.
Assessment of development variability was done by graphing the percentage of developed worms in DMSO controls for ABZ, IVM and MOX from S and V medium larval development assays in GraphPad Prism 5.0. Bartlett’s test was performed in R studio (v 4.2.0).
Results
Working with viscous medium
The adaption of the V medium from a long-term evolution experiment33 to a short-term phenotypic assay included changing media supplements of the V medium (Table 1). Papkou et al. found that adding trace metal solutions to V medium did not affect the worms' growth. We tested this idea and found that while no short-term effect was found on the worms grown in V medium with trace metal solutions over time, it was observed that there was a delay in the growth rate. Therefore, the trace metal solution was removed from further V medium experiments due to concerns that it was causing a change in the worms that we could not quantify.
Table 1.
Componenta | Viscous medium from Papkou et al. 2019 | Viscous Medium from this study |
---|---|---|
S basal Base: 10 mM Potassium Phosphate Buffer pH 6.0, 100 mM NaCl | ✔ | ✔ |
0.8% Hydroxypropylmethylcellulose | ✔ | ✔ |
10 mM Potassium Citrate buffer pH 6.0 | ✔ | ✔ |
Trace Metal Solution (55 uM disodium EDTA, 24 uM FeSO4 ·7H2O, 10 uM MnCl2·4H2O, 10 uM ZnSO4·7H2O, 1 uM CuSO4·5H2O) | ✔ | |
3 mM Mg2SO4 | ✔ | ✔ |
3 mM CaCl2 | ✔ | ✔ |
5 µg/ml cholesterol | ✔ | ✔ |
aFinal concentration in Viscous medium.
Further, the optimum OP50 density for worm populations ranging from 500 to 3000 worms had to be found in adapting the V medium for use with anthelmintics. Too much OP50 hampered viewing of the worms during counting stages, making it impossible to see if any worms survived treatment. Also, increasing the worm population within a well required an increased amount of OP50. We found that any worm population of 500 or less would not starve with an OP50 optical density (OD600) of 0.5 in the well. A 1000-worm population needed an OP50 density of 1 in the well to prevent starvation, and the 3000-worm population required an OP50 density of 3 in the well.
Life cycle of mutant Δpgp-9 (tm830) in V medium
We then tested how long a generation would take to develop, starting at an L1 stage. The experiment started with 1000 L1s per well in a 6-well microtiter plate. In an initial experiment, worms were incubated at 16 °C and 20 °C without shaking of the microtiter plate, resulting in death of all worms within 24 h, presumably due to a lack of oxygen. Therefore, all further experiments involved shaking the worms in the V medium at a constant speed of 150 rpm at 20 °C. The worms were analyzed for developmental stages every 24 h after the initial time point. Approximately 100 worms were counted in three different wells per time point. After 24 h, the majority of the worms were still in the L1 stage with a fraction of 0.896, with some having molted into the L2 stage (0.104) (Table 2). After 48 h, the worms were mainly at the L2 stage (0.646), with some L3 worms in the population (0.142) (Table 2). At 72 h, the worms were at the L3 stage (0.607), with a few L4/adults (0.125) present. The L4 worms were identified by the characteristic vulva bubble. At 96 h, most worms were L4/adults (0.644), with a few L1 worms (0.260) (Table 2). These L1 worms represented the offspring from the adults seen the days before (Fig. 2). With this growth cycle, it was concluded that the average time for molting and development is similar to the growth cycle observed on nematode growth agar31.
Table 2.
Hours | L1 stage | L2 stage | L3 stage | L4/adult stage |
---|---|---|---|---|
24 | 0.896 ± 0.032 | 0.104 ± 0.032 | 0 | 0 |
48 | 0.212 ± 0.033 | 0.646 ± 0.071 | 0.142 ± 0.051 | 0 |
72 | 0 | 0.267 ± 0.036 | 0.607 ± 0.030 | 0.125 ± 0.024 |
96 | 0.260 ± 0.064 | 0.017 ± 0.031 | 0.075 ± 0.022 | 0.644 ± 0.081 |
Additionally, we measured the average length, width, and volume of the C. elegans tm830 worms grown in either S medium, V medium or NGM agar at 20 °C for 72 h. The worms grown on NGM agar had an average length of 995.6 µm (± 135.7 µm, S.D.) and width of 119.1 µm (± 31.21 µm, S.D) (Fig. 2). Worms that were grown in S medium had an average length of 1164 µm (± 169.1 µm, S.D.) and width of 110.9 µm (± 33.27 µm, S.D.) (Fig. 2A,B). The difference of length and width between worms grown on NGM agar and S medium was statistically significant (Tukey’s method, P value < 0.0001) and this is similar to what has already been previously reported in the literature34. However, there was a small significant difference (Tukey’s method, P value < 0.05) in the volume of the worm although it has reported that though worms grown in S medium are longer and thinner than worms grown on NGM agar their volume should be similar (Fig. 2C)35. Worms grown in V medium had an average length of 1014 µm (± 155.0 µm, S.D.) (Fig. 2A). There was no significant difference in length between worms grown on NGM agar and those grown in V medium (ANOVA, P value 0.4938). However, there was a significant difference between S medium and V medium (Tukey’s method, P value < 0.0001). In addition, worms grown in V medium had the smallest width of 108.8 µm (± 42.38 µm, S.D.). The difference in width was not statistically different to S medium (ANOVA, P value 0.6391) but different to NGM agar (Tukey’s method, P value < 0.05) (Fig. 2B). Lastly, the volume of the worms grown in V medium was statistically different to both S medium (Tukey’s method, P value < 0.05) and NGM agar (Tukey’s method, P value < 0.05) (Fig. 2C). Therefore, worms grown in V medium have less volume than worms grown in S medium or on NGM agar.
Response to anthelmintics
Larval development assays are a standard assay to determine a drug’s effectiveness and it has the advantage that it can be used for all anthelmintic drug classes36,37. We tested the impact of the V medium on the EC50 value of C. elegans tm830 worms when exposed to various classes of anthelmintics. The EC50 values from the V medium were compared against EC50 values obtained from larval development assays of the worms in the standard S medium and NGM agar.
The first class of drugs tested were macrocyclic lactones which target GluCls, which leads to a flaccid response in the nematodes. Exposure of worms to IVM led to similar EC50 values with no significant difference between V (0.68 nM) or S medium (0.63 nM) (Fig. 3A, Table 3). Interestingly, there was a significant difference (P value < 0.0001) for the EC50 value when the worms were exposed to IVM in either S or V medium in comparison to NGM agar. On NGM agar the EC50 value was 1.92 nM, which was a 3.1 fold change in comparison to S medium and a 2.8 fold change in comparison to V medium (Table 3).
Table 3.
Drug | Medium | EC50 ± SE [nM] | 95% CI [nM] | R2 | Fold change | P Value |
---|---|---|---|---|---|---|
Ivermectin | S | 0.63 ± 0.01 | 0.57–0.67 | 0.952 | 0.93a | 0.236b |
V | 0.68 ± 0.01 | 0.61–0.70 | 0.967 | |||
NGM Agar | 1.92 ± 0.05 | 1.82–2.01 | 0.965 | 3.05c | < 0.0001e | |
2.82d | < 0.0001f | |||||
Moxidectin | S | 0.18 ± 0.04 | 0.15–0.22 | 0.910 | 0.90a | 0.407b |
V | 0.20 ± 0.009 | 0.19–0.21 | 0.977 | |||
NGM Agar | 1.94 ± 0.006 | 1.89–2.01 | 0.981 | 10.77c | < 0.0001e | |
9.70d | < 0.0001f | |||||
Levamisole | S | 5250 ± 18 | 4830–5707 | 0.919 | 1.02a | 0.633b |
V | 5100 ± 17 | 4703–5531 | 0.949 | |||
NGM Agar | 11,590 ± 21 | 10,500–12,780 | 0.961 | 2.21c | < 0.0001e | |
2.27d | < 0.0001f | |||||
Albendazole | S | 19,980 ± 91 | 13,396–34,434 | 0.840 | 1.16a | 0.546b |
V | 17,140 ± 58 | 13,152–22,335 | 0.911 | |||
NGM Agar | 150,800 ± 141 | 78,740–288,700 | 0.861 | 7.54c | < 0.0001e | |
8.79d | < 0.0001f |
Worms that developed into either the L4 or adult stage were counted as fully developed, while L1, L2, and L3 were considered not developed.
aCalculated as EC50 S medium/EC50 V medium.
bSum of squares F test comparing S medium to V medium.
cCalculated as EC50 NGM agar/EC50 S medium.
dCalculated as EC50 NGM agar/EC50 V medium.
eSum of squares F test comparing of NGM agar to S medium.
fSum of squares F test comparing of NGM agar to V medium.
Exposure to MOX, another macrocyclic lactone, also produced similar EC50 values for both V (0.20 nM) and S medium (0.19 nM) (Fig. 3B, Table 3) and the difference was not significant (P = 0.407). As above, the results for S or V medium were significantly different to those on NGM agar. This was due to the EC50 value of 1.94 nM on NGM agar, which is 10.77 and 9.70 fold higher than those for S and V medium, respectively (Table 3).
Albendazole, an anthelmintic belonging to the benzimidazole class, was also tested (Sharp, 1997). In the S medium, the EC50 value was 19.98 µM which was slightly higher than the EC50 value of 17.14 µM for the V medium (Fig. 3C, Table 3) but again this difference was not significant (P value = 0.546). However, the EC50 value in NGM agar was 150.8 µM, which is 7.54 fold higher than the EC50 value found in S medium and 8.79 fold higher than in V medium. The difference in the EC50 value between NGM agar and S/V medium was statistically significant (P value < 0.0001). The development curve for NGM agar was not able to reach a 0% development stage due to lack of solubility of albendazole in DMSO for the stock solution and for the serial dilution in agar. More DMSO could not be added to the wells as DMSO concentrations higher than 1% would inhibit worm development38.
Lastly, exposure of worms to a cholinergic agonist, levamisole, led to similar EC50 value of 5.25 µM in S and 5.10 µM in V medium, respectively (Fig. 3D, Table 3) indicating no significant difference (P = 0.633). The EC50 value on NGM agar was again significantly higher with 11.59 μM (Fig. 3D), which is twofold higher than the EC50 value obtained for S or V medium (P value < 0.0001) (Table 3).
Overall, our study demonstrated that more worms developed successfully in the V medium than in the S medium (Fig. 4). In V medium, the development percentage was 98.58% ± 1.65 whereas the S medium had a development percentage of 88.38% ± 8.52 (Table 4). Further, the variation in developmental rate is much higher in S medium than in V medium (Bartlett’s test, P value = 1.505 × 10–12) (Table 4). Therefore, the V medium was more consistent in obtaining developed worms than the S medium.
Table 4.
Medium | S | V |
---|---|---|
Meana | 88.38 ± 8.52 | 98.58 ± 1.65 |
P valueb | < 0.0001 | |
P valuec | 1.505 e-12 |
aStandard deviation is reported along with mean.
bP value determined by unpaired t test.
cP value determined by Barlett’s Test.
Discussion
The V medium was previously shown to be highly effective for performing evolution experiments with coevolving C. elegans and pathogenic Bacillus thuringiensis33. In this current study, the V medium was redesigned to test whether it can be used to determine effects of anthelmintic drugs as an alternative or even replacement to the commonly used S medium for phenotypic assays. More importantly, the use of V medium with anthelmintics implies that long term experiments could be designed to explore how anthelmintic resistance is generated. Since anthelmintic resistant worms were generated in the past on NGM agar (James and Davey, Menez 2016)21,39 the use of V medium may permit a more comprehensive, large-scale evaluation of resistance evolution, as the V medium facilitates parallel processing of a larger number of nematode populations33. Moreover, as seen with a higher EC50 generated on NGM agar the use of V medium could potentially lead to worm populations with a more realistic EC50 value as the worms are surrounded by the drug and not interacting with it through their cuticle contacting the agar surface. Also, as observed in Miltsch et al. the use of NGM agar for a phenotypic thrashing assay resulted in incomparable data, in contrast to what was observed before in any phenotypic assay using S medium40. The authors attributed this change of the data due to a long time delay between experiments but it could be caused by the crudely defined components of agar.
In our current study, C. elegans worms responded to anthelmintics at a similar EC50 value in V as in S medium. Moreover, we found that the V medium was easier to work with and manipulate. In our experience, it was however essential to adapt the worms to V medium for the success of any subsequent phenotypic assays. The adaptation over one to two generations in V medium from NGM agar allows any physiological and molecular changes associated with the new medium to occur before the planned experiments. A previous report regarding the change of the transcriptome of C. elegans N2 worms upon transfer from a solid to a liquid medium revealed that there was downregulation of genes for cephalic sheath cells and upregulation of genes in the TGF-beta signaling and WNT signaling pathways (Celen et al. 2018)41. However, use of V medium to support multiple generations from the initial thawing to phenotypic assays should prevent any sudden medium-dependent physiological responses by the worms, which otherwise may then interfere with the response to the anthelmintic drug.
The overall health of the worms was similar in V medium as on NGM agar. The growth of the worms in V medium was similar to the growth cycle of worms on NGM agar34,35. Other liquid sources used to grow worms such as the axenic liquid media (C. elegans maintenance medium) commonly used in metabolism studies can lead to delayed and often highly distorted development42. Therefore, V medium provides support to the worms to maintain their growth cycle. Further, the average length of worms grown in V medium was similar to those grown on NGM agar. This could be due to the stability of the cellulose matrix within V medium. Worms grown in S medium were statistically longer than worms grown on NGM agar or V medium. Worms grown in V medium were statistically smaller in width than those grown on either NGM agar or S medium and they had a lower volume overall. This indicates that though the worms grown in V medium have the same length as those grown on NGM agar they overall are smaller than worms grown in S medium or on NGM agar. However, V medium does provide an environment that allows C. elegans to fully develop into adult worms in a completely defined medium and without growing on (NGM) agar.
Notably, our results show that when using the V medium to test various anthelmintics there were no significant differences in EC50 values compared to the S medium. The highest difference between both media was observed for albendazole and even here only a 16% higher EC50 value was obtained for S medium. In contrast, when comparing the EC50 between NGM agar and any of the liquid media, it was apparent that the EC50 value changed substantially and significantly, up to more than 280% for IVM. This could be because anthelmintics did not diffuse evenly in the NGM agar, or the worms were not immersed in medium containing the drugs. Therefore, the drug was not able to interact with the full worm cuticle but only a part of it exposed to the agar. Therefore, these results suggest that either S or V medium should be used when conducting larval development assays with anthelmintics, whereas assays on NGM agar appear to produce high EC50 values. Lastly, worms grown in V medium had a more even rate of development than in S medium. Moreover, worms in S medium were 10% less developed than in V medium and more variable. This variability was determined to be significant between the two medias by Bartlett’s test with a p value of 1.505 × 10–12 (Table 4). The difference in development can also be seen in the development assays as the V medium curve is higher than the S medium curve for all of the anthelmintics tested.
Overall, we can conclude that V medium appears to be a medium type that would support long-term multigenerational drug activity studies. It can support worm growth at a similar rate as is observed on NGM agar, since worms develop as they do on NGM agar. Moreover, the previous study by Papkuo et al. 2019 already showed that the V medium supports efficient mating of nematodes, in contrast to the liquid S medium33. At the same time, when worms are exposed to anthelmintics their response is similar to that in S medium. The cellulose matrix in the V medium is dense enough to support worm growth yet it allows the worms to be fully interactive with anthelmintics as in liquid media. Therefore, the V medium could be used for long-term multigenerational drug activity studies.
The use of the V medium could also facilitate analysis of other drug delivery systems since C. elegans have been used in high throughput drug screens to understand drug mechanics, neurodegenerative diseases and test antimicrobials and antifungals43–46. We propose that instead of using S medium for many of these assays that only span one generation to use instead V medium to build multigenerational experiments. This would allow researchers a larger downstream prospective on the effects of these drugs especially on any phenotypic defect that could affect offspring viability and performance. As the V medium was previously shown by Papkou et al. (2019) to be effective in evolution experiments, it would be interesting to study other pathogens such as Pseudomonas or Stapholycoccus and see if they have the same mechanism of killing as observed before on agar6. Further, V medium allows us to study the effects of pathogenic bacteria and also other types of drugs, such as antimicrobials or additional anthelmintics, on the progeny of the worms as well as resulting resistance evolution, which is not possible in the standard S medium.
Acknowledgements
We would like to thank Agnes Piecyk for the initial discovery of Viscous medium as a C. elegans medium source. The funding from Collaborative Research Center 1182 (CRC 1182) on the Origin and Function of Metaorganisms, project A1.1 and the Volkswagen Foundation (96693).
Author contributions
J.R.H. performed research; J.R.H. and J.K analyzed data and wrote the main manuscript text and figures; H.S. provided the concept and background information; and G.S.H. revised manuscript and provided mentoring. All authors reviewed the manuscript. The authors declare no conflict of interest.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Data availability
All data generated or analysed during this study are included in this published article.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Schulenburg H, Félix MA. The natural biotic environment of Caenorhabditis elegans. Genetics. 2017;206(1):55–86. doi: 10.1534/genetics.116.195511. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Brenner S. The genetics of Caenorhabdztzs elegans. Genetics. 1974;77:71–94. doi: 10.1093/genetics/77.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Berman JR, Kenyon C. Germ-cell loss extends C. elegans life span through regulation of DAF-16 by kri-1 and lipophilic-hormone signaling. Cell. 2006;124:1055–1068. doi: 10.1016/j.cell.2006.01.039. [DOI] [PubMed] [Google Scholar]
- 4.Holden-Dye L, Walker RJ. Parasitic Helminths: Targets, Screens, Drugs and Vaccines. Wiley; 2012. How Relevant is Caenorhabditis elegans as a Model for the Analysis of Parasitic Nematode Biology. [Google Scholar]
- 5.Siddiqui SS. Metazoan motor models: Kinesin superfamily in C. elegans. Traffic. 2002;3(1):20–28. doi: 10.1034/j.1600-0854.2002.30104.x. [DOI] [PubMed] [Google Scholar]
- 6.Sifri CD, Begun J, Ausubel FM. The worm has turned–microbial virulence modeled in Caenorhabditis elegans. Trends Microbiol. 2005;13(3):119–127. doi: 10.1016/j.tim.2005.01.003. [DOI] [PubMed] [Google Scholar]
- 7.Laing ST, Ivens A, Butler V, et al. The transcriptional response of Caenorhabditis elegans to ivermectin exposure identifies novel genes involved in the response to reduced food intake. PLoS One. 2012;7(2):e31367. doi: 10.1371/journal.pone.0031367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Burns AR, Luciani GM, Musso G, et al. Caenorhabditis elegans is a useful model for anthelmintic discovery. Nat. Commun. 2015;6(May):1–11. doi: 10.1038/ncomms8485. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Widmayer SJ, Crombie TA, Nyaanga JN, Evans KS, Andersen EC. C. elegans toxicant responses vary among genetically diverse individuals. Toxicology. 2022;479:153292. doi: 10.1016/j.tox.2022.153292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hahnel SR, Dilks CM, Heisler I, Andersen EC, Kulke D. Caenorhabditis elegans in anthelmintic research–old model, new perspectives. Int. J. Parasitol. Drugs Drug Resist. 2020;14:237–248. doi: 10.1016/j.ijpddr.2020.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Dent JA, Smith MM, Vassilatis DK, Avery L. The genetics of ivermectin resistance in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA. 2000;97(6):2674–2679. doi: 10.1073/pnas.97.6.2674. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Stasiuk SJ, Scott MJ, Grant WN. Developmental plasticity and the evolution of parasitism in an unusual nematode Parastrongyloides trichosuri. Evodevo. 2012 doi: 10.1186/2041-9139-3-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Fleming, J.T., Squire, M.D., Barnes, T.M., et al. Caenorhabditis elegans levamisole resistance genes Lev-1, Unc-29, and Unc-38 encode functional nicotinic acetylcholine receptor subunits. 1997. [DOI] [PMC free article] [PubMed]
- 14.Wei, J.Z., Hale, K., Carta, L., et al. Bacillus thuringiensis crystal proteins that target nematodes. www.pnas.orgcgi10.1073pnas.0538072100 [DOI] [PMC free article] [PubMed]
- 15.Schaeffer JM, Blizzard TA, Ondeyka J, Goegelman R, Sinclair PJ, Mrozik H. [3H] Paraherquamide binding to Caenorhabditis elegans: Studies on a potent new anthelmintic agent. Biochem. Pharmacol. 1992;43(4):679–684. doi: 10.1016/0006-2952(92)90230-G. [DOI] [PubMed] [Google Scholar]
- 16.Driscoll M, Dean E, Reilly E, Bergholz E, Chalfie M. Genetic and molecular analysis of a Caenorhabditis elegans beta-tubulin that conveys benzimidazole sensitivity. J. Cell Biol. 1989;109(6):2993–3003. doi: 10.1083/jcb.109.6.2993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Harder A, Schmitt-Wrede HP, Krücken J, et al. Cyclooctadepsipeptides-an anthelmintically active class of compounds exhibiting a novel mode of action. Int. J. Antimicrob. Agents. 2003;22(3):318–331. doi: 10.1016/S0924-8579(03)00219-X. [DOI] [PubMed] [Google Scholar]
- 18.Dent JA, Davis MW, Avery L. avr-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans. EMBO J. 1997;16(19):5867–5879. doi: 10.1093/emboj/16.19.5867. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Geary TG, Moreno Y. Macrocyclic lactone anthelmintics: spectrum of activity and mechanism of action. Curr. Pharm. Biotechnol. 2012;13(6):866–872. doi: 10.2174/138920112800399077. [DOI] [PubMed] [Google Scholar]
- 20.Wolstenholme AJ, Rogers AT. Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology. 2005 doi: 10.1017/S0031182005008218. [DOI] [PubMed] [Google Scholar]
- 21.Ménez C, Alberich M, Kansoh D, Blanchard A, Lespine A. Acquired tolerance to ivermectin and moxidectin after drug selection pressure in the nematode Caenorhabditis elegans. Antimicrob. Agents Chemother. 2016;60(8):4809–4819. doi: 10.1128/AAC.00713-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Jakobs N, Yilmaz E, Krücken J. Transgenic expression of Haemonchus contortus cytochrome P450 Hco-cyp-13a11 decreases susceptibility to particular but not all macrocyclic lactones in the model organism Caenorhabditis elegans. Int. J. Mol. Sci. 2022 doi: 10.3390/ijms23169155. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Fonseca BD, Diering GH, Bidinosti MA, et al. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J. Biol. Chem. 2012;287(21):17530–17545. doi: 10.1074/jbc.M112.359638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Pallotto LM, Dilks CM, Park YJ, et al. Interactions of Caenorhabditis elegans β-tubulins with the microtubule inhibitor and anthelmintic drug albendazole. Genetics. 2022 doi: 10.1093/genetics/iyac093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Lacey E, Gill JH. Biochemistry of benzimidazole resistance. Acta Trop. 1994;56:245–262. doi: 10.1016/0001-706X(94)90066-3. [DOI] [PubMed] [Google Scholar]
- 26.Lacey E. Mode of action of benzimidazoles. Parasitol. Today. 1990;6(4):112–115. doi: 10.1016/0169-4758(90)90227-U. [DOI] [PubMed] [Google Scholar]
- 27.Williamson SM, Robertson AP, Brown L, et al. The nicotinic acetylcholine receptors of the parasitic nematode Ascaris suum: Formation of two distinct drug targets by varying the relative expression levels of two subunits. PLoS Pathog. 2009;5(7):1–11. doi: 10.1371/journal.ppat.1000517. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Zheng SQ, Ding AJ, Li GP, Wu GS, Luo HR. Drug absorption efficiency in Caenorhbditis elegans delivered by different methods. PLoS One. 2013 doi: 10.1371/journal.pone.0056877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Bulterijs S, Braeckman BP. Phenotypic screening in C. elegans as a tool for the discovery of new geroprotective drugs. Pharmaceuticals. 2020;13(8):1–35. doi: 10.3390/ph13080164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Lehner B, Tischler J, Fraser AG. RNAi screens in Caenorhabditis elegans in a 96-well liquid format and their application to the systematic identification of genetic interactions. Nat. Protoc. 2006;1(3):1617–1620. doi: 10.1038/nprot.2006.245. [DOI] [PubMed] [Google Scholar]
- 31.Hope IAC. C. elegans: A Practical Approach. Oxford University Press; 1999. [Google Scholar]
- 32.Lewis JA, Fleming JT. Basic culture methods. Methods Cell Biol. 1995;48:3–29. doi: 10.1016/S0091-679X(08)61381-3. [DOI] [PubMed] [Google Scholar]
- 33.Papkou A, Guzella T, Yang W, et al. The genomic basis of red queen dynamics during rapid reciprocal host–pathogen coevolution. Proc. Natl. Acad. Sci. USA. 2019;116(3):923–928. doi: 10.1073/pnas.1810402116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Byerly L, Cassada RC, Russell RL. The life cycle of the nematode Caenorhabditis elegans I. Wild-type growth and reproduction. Dev. Biol. 1976;51:23–33. doi: 10.1016/0012-1606(76)90119-6. [DOI] [PubMed] [Google Scholar]
- 35.Moore BT, Jordan JM, Baugh LR. WormSizer: High-throughput analysis of nematode size and shape. PLoS One. 2013;8(2):57142. doi: 10.1371/journal.pone.0057142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Coles GC, Jackson F, Pomroy WE, et al. The detection of anthelmintic resistance in nematodes of veterinary importance. Vet. Parasitol. 2006;136(3–4):167–185. doi: 10.1016/j.vetpar.2005.11.019. [DOI] [PubMed] [Google Scholar]
- 37.Miltsch SM, Krücken J, Demeler J, Ramünke S, Harder A, von Samson-Himmelstjerna G. Interactions of anthelmintic drugs in Caenorhabditis elegans neuro-muscular ion channel mutants. Parasitol. Int. 2013;62(6):591–598. doi: 10.1016/j.parint.2013.05.006. [DOI] [PubMed] [Google Scholar]
- 38.Alokda A, Van Raamsdonk JM. Effect of DMSO on Lifespan and Physiology in C. elegans: Implications for Use of DMSO as a Solvent for Compound Delivery. [DOI] [PMC free article] [PubMed]
- 39.James CE, Davey MW. Increased expression of ABC transport proteins is associated with ivermectin resistance in the model nematode Caenorhabditis elegans. Int J Parasitol. 2009;39(2):213–220. doi: 10.1016/j.ijpara.2008.06.009. [DOI] [PubMed] [Google Scholar]
- 40.Miltsch SM, Krücken J, Demeler J, et al. Decreased emodepside sensitivity in unc-49 γ-aminobutyric acid (GABA)-receptor-deficient Caenorhabditis elegans. Int. J. Parasitol. 2012;42(8):761–770. doi: 10.1016/j.ijpara.2012.05.009. [DOI] [PubMed] [Google Scholar]
- 41.Çelen I, Doh JH, Sabanayagam CR. Effects of liquid cultivation on gene expression and phenotype of C. elegans. BMC Genomics. 2018;19(1):562. doi: 10.1186/s12864-018-4948-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Szewczyk NJ, Udranszky IA, Kozak E, et al. Delayed development and lifespan extension as features of metabolic lifestyle alteration in C. elegans under dietary restriction. J. Exp. Biol. 2006;209(20):4129–4139. doi: 10.1242/jeb.02492. [DOI] [PubMed] [Google Scholar]
- 43.Dranchak PK, Oliphant E, Queme B, et al. In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Dis. Models Mech. 2023 doi: 10.1101/2022.08.26.505462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Moy TI, Conery AL, Larkins-Ford J, et al. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem. Biol. 2009;4(7):527–533. doi: 10.1021/cb900084v. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Sohrabi S, Mor DE, Kaletsky R, Keyes W, Murphy CT. High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates. Commun. Biol. 2021 doi: 10.1038/s42003-021-01731-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.O’Reilly LP, Luke CJ, Perlmutter DH, Silverman GA, Pak SCC. elegans in high-throughput drug discovery. Adv. Drug Deliv. Rev. 2014;69–70:247–253. doi: 10.1016/j.addr.2013.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated or analysed during this study are included in this published article.